Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- ABBVIE INC.
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St George Hospital /id# 130356
Kogarah, New South Wales, Australia
- Alfred Health /id# 130353
Melbourne, Victoria, Australia
- Peter Maccallum Cancer Ctr /id# 130352
Melbourne, Victoria, Australia
- Hopital Haut-Lévêque /id# 134388
Pessac, Gironde, France
- Duplicate_hopital Universitaire Purpan /id# 134389
Toulouse, Haute-Garonne, France
- Ap-Hp - Hopital Saint-Louis /id# 130349
Paris, France
- Universitaetsklinikum Ulm /id# 130341
Ulm, Baden-Wurttemberg, Germany
- Universitaetsklinikum Leipzig /id# 130346
Leipzig, Saxony, Germany
- Universitaetsklinikum Carl Gustav Carus An Der Tu Dresden /id# 130342
Dresden, Germany
- Duplicate_klinikum Rechts Der Isar /id# 130347
Munich, Germany
- City of Hope /id# 129718
Duarte, California, United States
- University of California, Davis Comprehensive Cancer Center /id# 129719
Sacramento, California, United States
- Univ of Colorado Cancer Center /id# 127859
Aurora, Colorado, United States
- Emory Midtown Infectious Disease Clinic /id# 129715
Atlanta, Georgia, United States
- Northwestern University Feinberg School of Medicine /id# 128741
Chicago, Illinois, United States
- the University of Chicago Medical Center /id# 128742
Chicago, Illinois, United States
- Johns Hopkins University /id# 129699
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute /id# 127857
Boston, Massachusetts, United States
- Columbia University Medical Center /id# 130289
New York, New York, United States
- Duke Cancer Center /id# 129720
Durham, North Carolina, United States
- University of Texas Md Anderson Cancer Center /id# 127860
Houston, Texas, United States
- University of Texas Md Anderson Cancer Center /id# 141581
Houston, Texas, United States
- University of Washington /id# 129717
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Oct 2014
- Primary completion
- 16 Jun 2022
- Completion
- 16 Jun 2022
- Last update posted
- 16 May 2023
- Registered enrollment
- 212
- Registry id
- NCT02203773
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.